Matsuno H, Katayama K, Funahashi K, Saitoh M, Matsubara T. Choice of the most appropriate biological disease-modifying rheumatic drug for injection spacing: results from a multicentre observational study. Clinical and experimental rheumatology. 2019
Funahashi Keiko, Matsubara Tsukasa, Shono Esuke, Oribe Motohiro, Hashimoto Keisuke, Sagawa Akira, Yoshitama Tamami, Mitsuka Takeshi, Yoshida Tomohiko, Imai Atsuko, et al. COMPARISON OF THE INITIAL DIAGNOSTIC FINDINGS AND ONSET FACTORS OF RHEUMATOID ARTHRITIS (RA) IN ELDERLY ONSET RA AND ADULT ONSET RA BY MULTICENTER COHORT - ARE THERE ANY DIFFERENCES OF ONSET FACTORS? -. ANNALS OF THE RHEUMATIC DISEASES. 2019. 78. 1109
Takeuchi Tsutomu, Matsubara Tsukasa, Atsumi Tatsuya, Amano Koichi, Ishiguro Naoki, Sugiyama Eiji, Yamaoka Kunihiro, Genovese Mark C, Kalunian Kenneth, Walker David, et al. SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. ANNALS OF THE RHEUMATIC DISEASES. 2019. 78. 1686-1687
Ito H, Tsuji S, Nakayama M, Mochida Y, Nishida K, Ishikawa H, Kojima T, Matsumoto T, Kubota A, Mochizuki T, et al. Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs?. The Journal of rheumatology. 2019. 47. 4. 502-509
Matsuno H, Matsubara T. A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Modern rheumatology. 2018. 1-26
